Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Povorcitinib
Study Locations (20)
Florida
- Center For Clinical and Cosmetic Research — Aventura
- Schweiger Dermatology — Boca Raton
- Direct Helpers Research Center — Hialeah
- Skin Care Research, Llc — Hollywood
- Ziaderm Research, Llc — Miami
- Nodal Medical Center, Llc — Tampa
- Trueblue Clinical Research Moore Clinical Research, Inc McR Tampa Clinic Location — Tampa
Michigan
- Fivenson Dermatology — Ann Arbor
- Henry Ford Health System — Detroit
- Michigan Dermatology Institute — Waterford
Arizona
- Medical Dermatology Specialists Phoenix — Phoenix
- Investigate Md — Scottsdale
California
- First Oc Dermatology Research Inc — Fountain Valley
- Clinical Science Institute Clinical Research Specialists Inc — Santa Monica
Maryland
- University of Maryland School of Medicine — Baltimore
- Dermatology Associates Pc — Rockville
Kentucky
- Dermatology Specialists Research — Louisville
Massachusetts
- Metro Boston Clinical Partners — Brighton
New Hampshire
- Allcutis Research, Llc — Portsmouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2027-05-03 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06516965
The ClinicalTrials.gov registry entry for NCT06516965 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 163 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06516965 reports 20 study locations spanning 9 distinct geographic areas — top geographies include Florida, Michigan, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06516965 about?
NCT06516965 is a clinical study titled "A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)". The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
What is the current status of trial NCT06516965?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2024-10-10. Estimated completion is 2027-05-03.
What conditions does trial NCT06516965 study?
This clinical trial studies the following conditions: Prurigo Nodularis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06516965?
The interventions under investigation include: Placebo (DRUG), Povorcitinib (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06516965?
This trial is sponsored by Incyte Corporation, which has 163 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06516965 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.